ArticleCureus2026
Extranodal Natural Killer (NK)/T-Cell Lymphoma Causing Severe Facial Destruction Refractory to Chemotherapy and Immunotherapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL), is a rare, highly aggressive Epstein-Barr virus (EBV)-associated non-Hodgkin lymphoma. Diagnosis is frequently delayed because early presentation is often non-specific and may mimic many other conditions, including disseminated fungal or atypical bacterial infections, autoimmune conditions such as vasculitis, and other cutaneous malignancies, such as peripheral T-cell lymphomas or melanoma. We present a case of extensive, rapidly progressive and highly destructive necrotic facial and cutaneous lesions, which remained undifferentiated despite initial diagnostic workup, necessitating travel to a quaternary medical center on a medical visa for further evaluation. A thorough workup, including a histopathologic evaluation along with a positive EBV-encoded RNA in situ hybridization, confirmed ENKTCL. The patient's clinical course was marked by extensive local tissue destruction, EBV viremia, severe malnutrition, recurrent episodes of shock, and disease progression despite treatment with pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) and modified dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy and pembrolizumab. This case underscores the diagnostic challenges of ENKTCL and highlights the aggressive clinical course associated with delayed diagnosis and advanced-stage disease, emphasizing the importance of early histopathologic evaluation with EBV testing in patients with progressive necrotic midline lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.